<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24964084</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay.</ArticleTitle><Pagination><StartPage>e100545</StartPage><MedlinePgn>e100545</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e100545</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0100545</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease, associated with enterovirus 71 (EV71) infections, has recently become an important public health issue throughout the world. Serum neutralizing antibodies are major indicators of EV71 infection and protective immunity. However, the potential for cross-reactivity of neutralizing antibodies for different EV71 genotypes and subgenotypes is unclear. Here we measured the cross-reactive neutralizing antibody titers against EV71 of different genotypes or subgenotypes in sera collected from EV71-infected children and vaccine-inoculated children in a phase III clinical trial (ClinicalTrials.gov Identifier: NCT01636245) using a new pseudovirus-based neutralization assay. Antibodies induced by EV71-C4a were cross-reactive for different EV71 genotypes, demonstrating that C4a is a good candidate strain for an EV71 vaccine. Our study also demonstrated that this new assay is practical for analyses of clinical samples from epidemiological and vaccine studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huafei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hongxia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Henan Provincial Center for Disease Control and Prevention, Zhengzhou, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xueyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Henan Provincial Center for Disease Control and Prevention, Zhengzhou, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shijie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, the First Hospital of Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, the First Hospital of Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Life Science, Xiamen University, Xiamen, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Life Science, Xiamen University, Xiamen, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Weiheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China; Key Laboratory for Molecular Enzymology &amp; Engineering, Ministry of Education, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China; Key Laboratory for Molecular Enzymology &amp; Engineering, Ministry of Education, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Jilin University, Changchun, P. R. China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, P. R. China; Key Laboratory for Molecular Enzymology &amp; Engineering, Ministry of Education, Jilin University, Changchun, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01636245</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.7</RegistryNumber><NameOfSubstance UI="D049409">Luciferases, Firefly</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="Y">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049409" MajorTopicYN="N">Luciferases, Firefly</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="Y">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24964084</ArticleId><ArticleId IdType="pmc">PMC4070950</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0100545</ArticleId><ArticleId IdType="pii">PONE-D-14-11398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yi L, Lu J, Kung HF, He ML (2011) The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol 37: 313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, et al. (2013) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 31: 425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zhu S, Guo X, Wang J, Wang D, et al. (2010) Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J 7: 300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989968</ArticleId><ArticleId IdType="pubmed">21050463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ LE, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancil J DL, Maresova V, Hruskova J (1985) 2 cases of meningeal syndrome, probably caused by enterovirus 71 (EV71). Cesk Pediatr 40: 731&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">4085024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, VM, Shindarov L, Lavrova I, Gracheva L, et al. (1979) Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60: 329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa C OM, Watanabe H, Fujimoto J, Kinbara K, Tanaka H (1980) Epidemic of hand, foot and mouth disease in Gifu Prefecture in 1978. Jpn J Med Sci Biol 33: 167&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6259389</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T LP, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YP, Lin TL, Hsu LC, Chen YJ, Tseng YH, et al. (2010) Genetic diversity and C2-like subgenogroup strains of enterovirus 71, Taiwan, 2008. Virol J 7: 277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975644</ArticleId><ArticleId IdType="pubmed">20959020</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, et al. (2001) Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol 75: 7732&#x2013;7738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders SA, Herrero LJ, McPhie K, Chow SS, Craig ME, et al. (2006) Molecular epidemiology of enterovirus 71 over two decades in an Australian urban community. Arch Virol 151: 1003&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, et al. (2003) Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis 9: 461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, et al. (2009) Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 62: 254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Z, Tan XJ, Shao JJ, Zhang Y, Kuang XZ, et al. (2010) [Epidemiology and etiology of hand-foot-and-mouth disease in Shanghai, 2009]. Bing Du Xue Bao 26: 437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">21344746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PV, Thao NT, Perera D, Huu TK, Tien NT, et al. (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13: 1733&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YP, Lin TL, Kuo CY, Lin MW, Yao CY, et al. (2008) The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007. Virus Res 137: 206&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18706461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, et al. (2011) The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 6: e25662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, et al. (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 381: 2024&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, et al. (2013) The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One 8: e79599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386&#x2013;9395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, et al. (2009) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27: 3153&#x2013;3158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun Jin, LX, Shi-jie GUO, Shi-yang Sun, Shu Zhang, et al. (2012) Safe and Objective Assay of Enterovirus 71 Neutralizing. CHEM RES CHINESE UNIVERSITIES 28: 91&#x2013;95.</Citation></Reference><Reference><Citation>Li X, Fan P, Jin J, Su W, An D, et al. (2013) Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. Virol J 10: 250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3765843</ArticleId><ArticleId IdType="pubmed">23919614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, et al. (2013) Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One 8: e56341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, et al. (2010) An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 7: 94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Mao Q, Yao X, Chen P, Chen X, et al. (2013) Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One 8: e64116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673970</ArticleId><ArticleId IdType="pubmed">23755115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488738</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicat JM, Blum D, Wion D, Benabid AL, Berger F (1998) RLU and studies using the luciferase reporter gene. Nat Biotechnol 16: 702.</Citation><ArticleIdList><ArticleId IdType="pubmed">9702756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Wang W, Wen Z, Song A, Hong K, et al. (2012) Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China. J Virol Methods 185: 267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang J, Guo W, Wang H, Zhu S, et al. (2011) Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the Central Plain of China. PLoS One 6: e27895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220707</ArticleId><ArticleId IdType="pubmed">22125635</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Ma H, Xu L, An D, Sun S, et al. (2013) Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum. J Virol Methods 187: 362&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112850</ArticleId><ArticleId IdType="pubmed">23178532</ArticleId></ArticleIdList></Reference><Reference><Citation>McCutchan FE, Viputtigul K, de Souza MS, Carr JK, Markowitz LE, et al. (2000) Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. AIDS Res Hum Retroviruses 16: 801&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">10826486</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11714622</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985706</ArticleId></ArticleIdList></Reference><Reference><Citation>DiazGranados CA, Denis M, Plotkin S (2012) Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 31: 49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">23142300</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, et al. (2013) Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLoS One 8: e79783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Chiang PS, Chia MY, Luo ST, Chang LY, et al. (2013) Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development. PLoS Negl Trop Dis 7: e2067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573098</ArticleId><ArticleId IdType="pubmed">23459633</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Chen W, Chang H, Tang R, Zhao J, et al. (2010) Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes 41: 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20306124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhu C, Bao W, Zhao K, Niu J, et al. (2012) Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One 7: e32405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315555</ArticleId><ArticleId IdType="pubmed">22479324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JS, Zhao N, Pan H, Wang CM, Wu B, et al. (2013) Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and 2013. J Virol Methods 193: 713&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933074</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30: 3295&#x2013;3303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, et al. (2013) Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 20: 1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Li N, Yu X, Yao X, Li F, et al. (2012) Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 157: 37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, He Y, Yang H, Zhu J, Xu X, et al. (2005) Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol 43: 3835&#x2013;3839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang D, Yan D, Zhu S, Liu J, et al. (2010) Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol 48: 619&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815627</ArticleId><ArticleId IdType="pubmed">20018819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, et al. (2012) A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 86: 11967&#x2013;11976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Han X, Wang G, Hu W, Zhang W, et al. (2011) Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis 17: 1537&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381541</ArticleId><ArticleId IdType="pubmed">21801645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>